Search results
Your employer offers a 401(k) that includes free retirement planning. Is that enough?
Market Watch· 2 hours ago1. Do you take full advantage of the professional advice you can get for free? In a 2023 survey by...
Opinion | Note to Fed: It’s okay to cut interest rates now
Washington Post· 3 hours agoJim Parrott is co-owner of Parrott Ryan Advisors and a nonresident fellow at the Urban Institute....
FDA advisers urge targeting JN.1 strain in recipe for fall's COVID vaccines
KEYT 3 Santa Barbara· 15 hours agoGovernment advisers say it’s time to update the recipe for the COVID-19 vaccines Americans will...
Ulta Beauty Lowers Guidance, but Is There a Buying Opportunity With the Stock Down Nearly 25% off...
Motley Fool via Yahoo Finance· 37 minutes agoShould you invest $1,000 in Ulta Beauty right now? Before you buy stock in Ulta Beauty, consider...
COVID shots should target variants with JN.1 lineage in 2024-25 campaign, US FDA advisers say
Reuters via Yahoo News· 1 day agoThe 16 advisors did not vote on whether to favor the original JN.1 variant or one of its successors...
Here's Why Shares in this Housing Related Stock Slumped in May
Motley Fool via Yahoo Finance· 50 minutes agoShould you invest $1,000 in Jeld-wen right now? Before you buy stock in Jeld-wen, consider this: The...
First Trust Advisors LP Raises Stock Position in AstraZeneca PLC (NASDAQ:AZN)
ETF DAILY NEWS· 5 hours agoFirst Trust Advisors LP grew its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 7.4% in the fourth quarter, according to its most recent filing with the Securities ...
Transworld Business Advisors CEO Inducted to International Business Brokers Association Inaugural...
Digital Journal· 6 hours ago"I'm so grateful to be...
What Is the Dividend Payout for UPS Stock?
Motley Fool via Yahoo Finance· 52 minutes agoShould you invest $1,000 in United Parcel Service right now? Before you buy stock in United Parcel Service, consider this: The Motley Fool Stock Advisor...
MDMA drug for PTSD panned by FDA advisers citing trial flaws - The Boston Globe
The Boston Globe· 17 hours agoThe psychedelic drug MDMA failed to get backing from US regulatory advisers to treat a form of...
